RxDoctor Payments Data

Stacy Centeno

Nurse Practitioner · Sarasota, FLNPI 1508215450

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $54,856 of the $72,530 with a category attached, or 75.6%. 16 manufacturers reported payments, led by Dexcom, Inc. at 47.9% of the total. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$72,530in general payments, 2019–2025

Across 176 payments — averaging $412.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$35K
  • Novo Nordisk$28K
  • Abbott$7K
  • Bayer$349
  • Amgen$347
  • Xeris Pharmaceuticals, Inc.$323
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$4,4176%
  • Speaking & faculty fees$54,85676%
  • Travel & lodging$7,33010%
  • Food & beverage$5,8478%
  • Education$200%
  • Gifts$590%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,530 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide916$1,192,325
OzempicSemaglutide626$958,097
Tresiba Flextouch U-200Insulin Degludec367$514,006
JardianceEmpagliflozin184$287,104
RybelsusSemaglutide138$212,095
Humulin R U-500 KwikpenInsulin Regular, Human109$171,991
TrulicityDulaglutide124$171,003
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog93$165,288
FarxigaDapagliflozin Propanediol112$134,518
Xultophy 100-3.6Insulin Degludec/Liraglutide60$131,307
Fiasp FlextouchInsulin Aspart (Niacinamide)98$101,362
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/767$99,959
Tresiba Flextouch U-100Insulin Degludec87$60,818
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog57$53,049
Synjardy XrEmpagliflozin/Metformin Hcl31$53,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog$129$1,396,7451,098 claims
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Fiasp, Novolog$28,449$1,352,799898 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$176$44,78748 claims
BayerKerendia$349$32,86326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →